Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Sells $666,037.26 in Stock

Key Points

• Amneal Pharmaceuticals' EVP, Nikita Shah, sold 71,694 shares of stock valued at $666,037.26, reducing ownership by 21.15%.
• The company's stock has a current trading price of $9.45 and has a market capitalization of $2.96 billion.
• Amneal Pharmaceuticals beat earnings projections with $0.23 earnings per share, surpassing analysts' expectations of $0.17.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) EVP Nikita Shah sold 71,694 shares of the business's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $9.29, for a total value of $666,037.26. Following the transaction, the executive vice president owned 267,235 shares of the company's stock, valued at $2,482,613.15. The trade was a 21.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Nikita Shah also recently made the following trade(s):

• On Tuesday, August 12th, Nikita Shah sold 50,000 shares of Amneal Pharmaceuticals stock. The stock was sold at an average price of $9.04, for a total value of $452,000.00.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock traded up $0.06 during trading hours on Friday, hitting $9.45. The stock had a trading volume of 1,860,281 shares, compared to its average volume of 1,695,659. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of 945.95 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a one year low of $6.68 and a one year high of $9.59. The stock's 50-day moving average price is $8.21 and its two-hundred day moving average price is $7.98.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. As a group, equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. The Goldman Sachs Group initiated coverage on Amneal Pharmaceuticals in a report on Friday, June 6th. They set a "buy" rating and a $12.00 target price on the stock. Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $11.60.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds have recently made changes to their positions in AMRX. Vanguard Group Inc. lifted its holdings in Amneal Pharmaceuticals by 6.2% in the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after buying an additional 920,758 shares in the last quarter. Rubric Capital Management LP lifted its stake in Amneal Pharmaceuticals by 9.1% during the second quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company's stock valued at $94,737,000 after purchasing an additional 974,355 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Amneal Pharmaceuticals by 5.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company's stock valued at $39,531,000 after acquiring an additional 278,653 shares in the last quarter. Nantahala Capital Management LLC lifted its position in Amneal Pharmaceuticals by 14.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company's stock worth $35,333,000 after buying an additional 558,877 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Amneal Pharmaceuticals by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 3,813,207 shares of the company's stock valued at $30,207,000 after purchasing an additional 26,536 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.